Will Reeve, an ABC News correspondent and son of "Superman" actor Christopher Reeve, has revealed his battle with testicular ...
AstraZeneca Puts $2 Billion Behind Summit's Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio / ADC, Akeso ...
1d
Lindsay Clancy set to return to court for first time since murder trial ended with deadlocked jury
Lindsay Clancy is set to return to court Tuesday for a hearing that could help decide whether she will face a second trial in ...
Chronic pancreatitis is characterised by complex, multifactorial pain affecting 80–90% of patients. Pain arises from overlapping nociceptive and neuropathic mechanisms, often accompanied by CNS ...
Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has ...
The head of Ethiopia’s army suggested that neighboring Eritrea, Sudan and Egypt were supporting rebel troops who have ...
Research that won the 10th Bioindustry AwardOn July 15, 2026, Sumitomo Pharma Co., Ltd. and RACTHERA Inc. announced that the ...
Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.
JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...
AstraZeneca’s supplemental Biologics License Application for Imfinzi in combination with enfortumab vedotin has been accepted and granted Priority Review by the US FDA for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results